首页> 外文期刊>Case Reports in Medicine >Rituximab Efficacy during a Refractory Polyarteritis Nodosa Flare
【24h】

Rituximab Efficacy during a Refractory Polyarteritis Nodosa Flare

机译:难治性多发性结节性火斑发作期间利妥昔单抗的疗效

获取原文
       

摘要

Polyarteritis nodosa (PAN) is a systemic vasculitis whose severe forms are treated with glucocorticoids and cyclophosphamide. Refractory patients are exposed to many complications, notably accelerated atherosclerosis. We report a case report of 71-year-old man followed for polyarteritis nodosa refractory to glucocorticoids and cyclosphosphamide. Systemic vasculitis relapses are followed to accelerated atherosclerosis: severe ischemic lesions led to amputation of lower limbs. Remission of refractory PAN is obtained with rituximab. Disappearance of biological inflammatory is allowed to regression of ischemic lesions in upper limbs. In this situation, we recommend a systematic vascular work-up for patients suffered from refractory vasculitis. On the other hand, therapeutic trials are needed to determine the real efficacy and place of rituximab in the treatment of polyarteritis nodosa.
机译:结节性多发性动脉炎(PAN)是一种全身性血管炎,其严重形式已用糖皮质激素和环磷酰胺治疗。难治性患者面临许多并发症,特别是动脉粥样硬化的加速。我们报道一例71岁男性因糖皮质激素和环磷酰胺难治的多发性结节性动脉炎的病例报道。系统性血管炎复发后,动脉粥样硬化加速:严重的缺血性病变导致下肢截肢。利妥昔单抗可缓解难治性PAN。生物炎症的消失使上肢缺血性病变消退。在这种情况下,我们建议对难治性血管炎患者进行系统的血管检查。另一方面,需要进行治疗试验以确定利妥昔单抗在结节性多发性动脉炎治疗中的真正功效和位置。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号